Safety and Efficacy Study of PRV111 in Subjects With Oral Squamous Cell Carcinoma

NCT03502148 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Oral Squamous Cell Carcinoma

Interventions

DRUG: PRV111 (Cisplatin Transmucosal System)

Sponsor

Privo Technologies

Collaborators

[object Object]